What is market sentiment?

Market sentiment is the overall attitude of investors toward a particular security or the financial market as a whole. It reflects whether investors are feeling bullish (optimistic) or bearish (pessimistic) based on price action, news flow, economic indicators, and collective psychology. Kinvestor tracks real-time market sentiment across major indices and individual equities.

How does financial news affect stock prices?

Financial news affects stock prices by shifting investor sentiment. Positive earnings reports, strong economic data, or favorable Fed decisions typically boost stock prices, while negative news can trigger sell-offs. The speed and magnitude of price moves depends on whether the news beats or misses market expectations.

What are stock market movers?

Stock market movers are stocks with significant price changes — either up (gainers) or down (losers) — within a trading session. Movers are typically driven by earnings reports, analyst upgrades or downgrades, macroeconomic news, or major corporate announcements. Kinvestor tracks the biggest movers in real time across the S&P 500, NASDAQ, and Dow Jones.

What is earnings season?

Earnings season is the period each quarter when publicly traded companies report their financial results. It occurs four times per year: January–February (Q4 results), April–May (Q1 results), July–August (Q2 results), and October–November (Q3 results). During earnings season, stocks often experience heightened volatility as results beat or miss analyst expectations.

What is financial intelligence?

Financial intelligence is the ability to understand and interpret financial data, market trends, news, and sentiment to make informed investment decisions. It combines real-time market data, news aggregation, sentiment analysis, and economic indicators into actionable insight. Kinvestor is a financial intelligence platform that aggregates these signals in one place.

◆ NeutralPMN

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

GlobeNewswire Inc.·July 28, 2026

ProMIS Neurosciences announced positive interim results from its Phase 1b PRECISE-AD trial of PMN310, an experimental Alzheimer's disease treatment. The drug showed a favorable safety profile with no ARIA-E cases across all genotypes including high-risk APOE4 carriers, and demonstrated early biomarker movement consistent with target engagement. Full 12-month topline results are expected in Q1 2027.

Read Full Article at GlobeNewswire Inc. →

← Back to Financial Intelligence